It is amusing to watch the "him" card get played...Advancing the bullboard scam in the midst of tax loss season is an ideal way to further confirm the value of the paper. If you think that the board, led by the former CEO of Sieman's Global Diagnostic division based here in the US, decided on a fine young gent with no biotech experience, running a nanocap pot play for no reason think again. The current chair of EDT has held the "chair" for well over a decade. He recently bought $180,000 CAD of the $10M CAD taken in the bought deal by AGP of New York. As Ive mentioned once or twice before "they own it all", they have more approvals on display in their restroom than most Canadien biotechs will ever achieve. Hi-liting "him" ( the young 19 penny USD scapegoat )and his purposeful and planned activity is all part of tax loss strategy and nicely validates the ridiculous 42.5 cent handout to their American supporters. Didnt David get 15 thumbs for suggesting "he" was the problem? Wink wink we believe ;- )
Pay attention, you're being "had" and it is because we have 5 existing FDA approvals and are seemingly pumping the brakes on finalizing #6 with a 5 year low in the middle of "tax loss season"... must be more coincidence ;- )
It is a social media / bullboard SCAM. Don't advance the drama and the agenda by piling the bull even higher than they are. The value of the paper is best displayed by the Beech Boys attempts to "taint it". A SCAM and in my very humble opinion, very valuable paper with 20 year long bullboard escorts selling the tale all the way to the "market" ( see the three little pigs )
Ive got more, but will share later
Buena suerte,
Thome